[{"data":1,"prerenderedAt":212},["ShallowReactive",2],{"story-209156-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":40,"questions":41,"relatedArticles":66,"body_color":210,"card_color":211},"209156",null,"Generic Drug Tariffs 100-200% | Supply Chain Disruption & Sourcing Opportunities 2026-2028","- India supplies 50% of US generic drugs; tariff escalation from 0% (Aug 2026) to 100% (Aug 2028) to 200% creates 24-month arbitrage window for cross-border sellers and supply chain repositioning",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"https://www.thedailyupside.com/wp-content/uploads/2026/07/sipaphotostwentyseven302363-scaled-e1784747100924.jpg","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iTG5a9KYFIV0/v32/-1x-1.webp","https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","https://www.dcatvci.org/wp-content/uploads/2025/02/iStock-1001502582-1.jpg","https://images.unsplash.com/photo-1494412685616-a5d310fbb07d?crop=entropy&cs=tinysrgb&fit=max&fm=jpg&ixid=M3wyNzUwNjN8MHwxfHNlYXJjaHwxOHx8dHJhZGV8ZW58MHx8fHwxNzg0Nzk5NjA5fDA&ixlib=rb-4.1.0&q=80&w=1080","https://assets.newsweek.com/wp-content/uploads/2026/07/GettyImages-1458838272-Custom.jpg","https://image.cnbcfm.com/api/v1/image/108144276-17470722822025-05-12t173618z_940040002_rc2yj8abm3ue_rtrmadp_0_usa-trump-drugpricing.jpeg?v=1747072307&w=1600&h=900","https://imageio.forbes.com/specials-images/imageserve/6a60daaff73e4d8265aad21e/Variety-Of-Pills-And-Capsules--Close-Up-/1960x0.jpg?height=473&width=711&fit=bounds","https://static.time.com/v3/assets/bltea6093859af6183b/blt50b7a93ab56492f0/6a62639d85ffee2dd527c62e/Generic-Drugs-Tariffs.jpg?branch=production&width=3840&quality=75&auto=webp&crop=3:2","https://www.politico.eu/cdn-cgi/image/width=1160,height=773,quality=80,onerror=redirect,format=auto/wp-content/uploads/2026/07/22/GettyImages-2248128894-scaled.jpg","https://image.cnbcfm.com/api/v1/image/108336351-1784251467141-gettyimages-2285785852-AFP_C2EX37T.jpeg?v=1784251495&w=1600&h=900","https://s.yimg.com/lo/mysterio/api/DCEBFB9D124710093000442BCFCF33B3A9389C2824482FF875B6FFC9004254B9/subgraphmysterio/resizefit_w960_h540;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fwfrv_articles_965%2Fb358993f5d7337faae6dd3dc29b27adb","https://thehill.com/wp-content/uploads/sites/2/2026/07/6a465e97c4ede0.46237411.jpeg?strip=1","https://cdn.sanity.io/images/0vv8moc6/pharmexec/b2defa6b4904a34b5dfa8d86ebaaae1c7a81931b-1280x720.png/pharma%20finance%2016x9.png?w=1280&max-h=720&fit=crop&auto=format","https://www.washingtonexaminer.com/wp-content/uploads/2025/12/iStock-1202498704-e1784730318924.jpg?resize=1200,683","https://imgproxy.divecdn.com/nPow6DTNGLvXiFogeQ3sE2l5JX3D825iebn7hUK0MyU/g:nowe:0:0/c:3200:1807/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjg3MTgyNTQxLmpwZw==.webp","https://www.reuters.com/resizer/v2/G2BIKLLJRRKY5JPCQI63HTFJP4.jpg?auth=c6d554ac3f68d346fa23813b1ff67b1cbd40a92f96675edec338f79a473f6769&width=1920&quality=80","https://ednews.net/en/wp-content/uploads/sites/2/2026/07/Medicines-1024x536.webp","https://static.toiimg.com/thumb/msid-132562787,width-1280,height-720,imgsize-993014,resizemode-4,overlay-toi_sw,pt-32,y_pad-600/photo.jpg","https://s.yimg.com/lo/mysterio/api/604f3fa622713b9b6b519fcee36a5a84de8932d922d49968d59e973fca4faa1b/lightyear_networkapi/resizefill_w960;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fmeidastouch_articles_379%2F39413ffd202eafcc3ff4c3822d199361","https://www.businessreport.com/wp-content/uploads/2026/06/Business-Report-2026-default-image.jpg","https://imgproxy.divecdn.com/byxOD3GwWuBHXrMYAYKAG78Qufhw3izUBK9blhky4No/g:nowe:0:0/c:3200:1807/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjgxMTE5MDMyLmpwZw==.webp","https://www.reuters.com/resizer/v2/JTZILSYETBONLGHQ5Q64GURKGI.jpg?auth=f7a35164f246bd5265b2af2a5678f8c5161a8262bb50e1867437b136b85950b6&width=1920&quality=80","https://prosperousamerica.org/wp-content/uploads/2026/07/medicine-cabinet-featured.jpg","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iggATuYA33mk/v3/620x-1.jpg","https://images.wsj.net/im-360236?width=700&height=466","https://ca-times.brightspotcdn.com/dims4/default/d50d5cd/2147483647/strip/true/crop/2000x1333+0+0/resize/1200x800!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F78%2Ff8%2Fe4999cbbe42dafd550c635ba21b7%2F1x-1.jpg","https://cdn.i-scmp.com/sites/default/files/styles/700x400/public/d8/images/canvas/2026/07/22/96667156-e9ce-427b-9571-2c23ce482933_8c988789.jpg?itok=cFaU2nHw&v=1784712882","https://cdn.thepharmaletter.com/files/2024/04/e6d4e500-0153-11ef-a588-e798d47e404e-generic_big.jpg","https://assets3.cbsnewsstatic.com/hub/i/r/2026/07/22/accdc016-425c-41ab-ad52-b2fb05e25a96/thumbnail/1200x630/2b0e0f907067b0639b119bf5e0e819f2/gettyimages-1220583234.jpg","**Trump's proposed tariff policy on imported generic medicines creates a critical 24-month arbitrage window for cross-border e-commerce sellers and supply chain strategists.** The policy imposes zero duties for two years starting August 1, 2026, followed by 100% tariffs in August 2028 and 200% annually thereafter. With India supplying approximately 50% of US generic drugs and China supplying roughly 80% of active pharmaceutical ingredients (APIs), this policy fundamentally reshapes sourcing economics for health and wellness sellers operating on Amazon, eBay, and specialty health platforms.\n\n**The tariff structure creates immediate competitive advantages for sellers with domestic US sourcing or alternative supply chains.** Generic manufacturers operate on single-digit profit margins (typically 3-8%), making tariffs of 100-200% economically devastating—consultant Salil Kallianpur warned such tariffs constitute \"a market-exit notice\" for low-margin products. However, this creates a paradox: sellers with access to pre-tariff inventory or alternative sourcing can capture significant margin expansion. The global generic drug market is valued at nearly $500 billion, with generics representing 59% of US prescriptions but only a small share of overall drug spending due to low prices. For cross-border sellers, this means the 24-month grace period (August 2026-August 2028) represents a critical window to either: (1) accumulate inventory at current tariff rates, (2) establish alternative sourcing from Vietnam, Mexico, or domestic US suppliers, or (3) pivot to higher-margin branded or specialty pharmaceutical products.\n\n**India-specific trade tensions compound the tariff risk for sellers sourcing from Indian manufacturers.** News reports indicate Trump administration policies are creating additional trade pressures on India beyond the generic drug tariffs. Indian pharmaceutical companies like Dr. Reddys Laboratories report US generic drug sales have declined from 50% to 27% of total revenue, with further contraction expected. Industry analysts at Nomura predict Indian manufacturers will likely maintain offshore operations rather than relocate to the US, instead raising prices to improve margins—a strategy that directly impacts sellers' cost of goods sold (COGS). For sellers currently sourcing health supplements, OTC medications, or wellness products from India, the combination of generic drug tariffs and broader US-India trade tensions creates supply chain risk. Building domestic generic manufacturing infrastructure requires 4-7 years minimum, making the two-year grace period insufficient for meaningful US production onshift. This means tariff escalation is likely to occur as planned, creating a hard deadline for sourcing strategy adjustments.",[42,45,48,51,54,57,60,63],{"title":43,"answer":44,"author":5,"avatar":5,"time":5},"What is the competitive advantage for sellers with domestic US sourcing or alternative supply chains?","Sellers with domestic US sourcing or non-India alternatives gain significant competitive advantages: (1) Cost structure: Avoid 100-200% tariffs, maintaining 8-15% margin advantage over India-sourced competitors post-August 2028, (2) Pricing flexibility: Can maintain lower retail prices while competitors face margin compression, (3) Supply chain resilience: Insulated from India-specific trade tensions and tariff escalation, (4) Market share capture: Can undercut competitors facing tariff exposure, particularly in price-sensitive health categories. Companies like Amphastar Pharmaceuticals, ANI Pharmaceuticals, Hikma, and Fresenius Kabi with substantial US production are positioned to gain market share. Sellers should evaluate partnerships with these domestic suppliers or consider private label arrangements. The 24-month grace period provides a window to establish domestic sourcing relationships before tariff escalation creates urgent supply chain pressure. Sellers who execute sourcing transitions by mid-2027 will have 12+ months to optimize operations before August 2028 tariff implementation.",{"title":46,"answer":47,"author":5,"avatar":5,"time":5},"How will generic drug tariffs impact consumer prices and seller demand on Amazon and eBay?","Generic drug tariffs will likely increase consumer prices by 15-30% based on Federal Reserve research showing previous Trump tariffs raised prices for core goods by 3.1% through February 2025. With generics representing over 90% of US prescriptions and nearly 50% of American adults reporting difficulty affording healthcare costs, price increases will reduce demand elasticity. Sellers should expect: (1) Reduced sales volume in price-sensitive health categories (2-5% decline in units), (2) Increased competition as sellers attempt to maintain market share through margin compression, (3) Shift toward higher-margin branded or specialty products. However, sellers with pre-tariff inventory or alternative sourcing can capture margin expansion. Amazon and eBay may implement category-specific pricing tools to help sellers manage tariff pass-through. Sellers should monitor competitor pricing strategies starting Q3 2026 to anticipate market dynamics before August 2028 tariff escalation.",{"title":49,"answer":50,"author":5,"avatar":5,"time":5},"What sourcing alternatives exist for sellers currently dependent on Indian suppliers?","Sellers have three primary alternatives: (1) Vietnam: Emerging pharmaceutical manufacturing hub with lower labor costs than India; consider suppliers in Ho Chi Minh City and Hanoi regions. (2) Mexico: USMCA trade agreement provides tariff advantages; Mexico has growing pharmaceutical manufacturing capacity, particularly for generics. (3) Domestic US suppliers: Companies like Amphastar Pharmaceuticals, ANI Pharmaceuticals, Hikma, and Fresenius Kabi have substantial US production and may offer competitive pricing to high-volume sellers. Sellers should conduct supplier audits by Q1 2026 to allow 6-12 months for transition. Vietnam and Mexico sourcing typically requires 60-90 days longer lead times than India, so inventory planning must account for extended supply chain timelines. Cost comparisons should include tariff impact: a $10 product from India faces $10-20 in tariffs (100-200%), while Vietnam/Mexico alternatives may offer 15-25% cost premiums but avoid tariff exposure.",{"title":52,"answer":53,"author":5,"avatar":5,"time":5},"How do broader US-India trade tensions beyond generic drugs affect cross-border sellers?","Trump administration policies create additional trade pressures on India beyond generic drug tariffs, affecting multiple product categories sourced from Indian suppliers. Cross-border sellers sourcing health supplements, textiles, electronics, or other products from India face compounding tariff risk. Indian pharmaceutical companies report declining US revenue (Dr. Reddys' US sales fell from 50% to 27% of total revenue), signaling broader market contraction. Sellers should: (1) Diversify sourcing across multiple countries to reduce India-specific risk, (2) Monitor US International Trade Commission announcements for additional India-targeted tariffs, (3) Evaluate supply chain resilience by stress-testing scenarios with 25-50% tariff increases, (4) Consider geographic hedging strategies that balance India sourcing with Vietnam, Mexico, or domestic alternatives. The broader trade tensions suggest tariff escalation beyond the announced generic drug policy is possible, making supply chain flexibility critical for long-term competitiveness.",{"title":55,"answer":56,"author":5,"avatar":5,"time":5},"What compliance and documentation requirements apply to generic drug imports during the grace period?","During the August 2026-July 2028 grace period, sellers must maintain standard FDA and customs documentation for pharmaceutical imports: (1) FDA registration and listing for facilities manufacturing imported drugs, (2) Customs entry documentation with HS Code 3004 classification, (3) Certificate of Analysis for active pharmaceutical ingredients, (4) Proof of origin for tariff classification purposes. Critical uncertainty exists regarding whether tariffs apply only to finished medicines or also to domestically-manufactured products using imported APIs. Sellers should request written clarification from US Customs and Border Protection (CBP) on their specific product classifications before August 2026. Documentation requirements may increase if CBP implements enhanced screening for API-containing products. Sellers should establish relationships with customs brokers experienced in pharmaceutical imports to ensure compliance and avoid delays. Non-compliance penalties can reach 20-25% of import value, making proper documentation essential.",{"title":58,"answer":59,"author":5,"avatar":5,"time":5},"How do Trump's generic drug tariffs affect cross-border sellers sourcing from India?","Trump's tariff policy creates a 24-month window of opportunity (August 2026-August 2028) before duties escalate from 0% to 100% to 200%. India supplies approximately 50% of US generic drugs, making Indian sourcing particularly vulnerable. Sellers currently importing health supplements, OTC medications, or wellness products from India should immediately audit their supply chains and consider: (1) accelerating inventory purchases before August 2026 to lock in current tariff rates, (2) diversifying sourcing to Vietnam, Mexico, or domestic US suppliers, or (3) shifting product mix toward higher-margin branded items. The two-year grace period is insufficient for manufacturers to relocate production (requiring 4-7 years), meaning tariff escalation is likely to occur as planned. Sellers with Indian suppliers should request written commitments on pricing through August 2028 to mitigate margin compression.",{"title":61,"answer":62,"author":5,"avatar":5,"time":5},"Which product categories face the highest tariff exposure under Trump's policy?","Generic medicines (HS Code 3004) face direct 100-200% tariffs, but cross-border sellers should also monitor: (1) Health supplements and OTC medications sourced from India (indirect exposure through API tariffs), (2) Wellness products containing pharmaceutical-grade ingredients, (3) Dietary supplements with active ingredients subject to API tariffs. The policy specifically targets finished generic drugs, but uncertainty remains regarding domestically-manufactured products using imported APIs. Sellers in these categories should prioritize sourcing diversification. Categories with the lowest tariff exposure include branded pharmaceuticals (which operate on higher margins and can absorb costs) and non-pharmaceutical health products. Sellers should calculate tariff impact by HS code using the US International Trade Commission's Harmonized Tariff Schedule database.",{"title":64,"answer":65,"author":5,"avatar":5,"time":5},"What is the timeline for generic drug tariff implementation and how should sellers prepare?","The tariff timeline is: 0% duties through July 31, 2026 (current baseline), 100% tariffs beginning August 1, 2028, and 200% annually thereafter. This creates three critical decision windows: (1) Immediate (now-July 2026): Evaluate current sourcing, negotiate long-term supplier contracts, and assess inventory accumulation ROI. (2) Mid-term (Aug 2026-July 2028): Execute sourcing diversification or domestic supplier transitions. (3) Escalation (Aug 2028+): Implement pricing adjustments or product portfolio shifts. Sellers should monitor US International Trade Commission announcements for implementation details, particularly clarification on whether tariffs apply only to finished medicines or also to drugs manufactured domestically using imported active pharmaceutical ingredients (APIs). This distinction significantly impacts sourcing strategy.",[67,72,76,80,84,88,92,97,101,105,109,113,117,121,125,129,133,137,141,145,149,153,157,161,165,169,173,178,182,186,190,194,198,202,206],{"id":68,"title":69,"source":70,"logo":5,"time":71},1288576,"EU shrugs off Trump's latest tariff threat on generics","https://www.euractiv.com/news/eu-shrugs-off-trumps-latest-tariff-threat-on-generics/","5D AGO",{"id":73,"title":74,"source":75,"logo":31,"time":71},1288553,"Trump threatens tariffs on imported generic drugs","https://www.biopharmadive.com/news/trump-tariffs-generic-drugs-pharmaceuticals-impact/825879/",{"id":77,"title":78,"source":79,"logo":17,"time":71},1288552,"The Potential Havoc Of Generic Drug Tariffs","https://www.forbes.com/sites/innovationrx/2026/07/22/the-potential-havoc-of-generic-drug-tariffs/",{"id":81,"title":82,"source":83,"logo":21,"time":71},1288556,"Trump threatens 100% generic drug tariffs beginning in 2028","https://finance.yahoo.com/economy/policy/articles/trump-threatens-100-generic-drug-152110997.html",{"id":85,"title":86,"source":87,"logo":25,"time":71},1288555,"Trump maps out 200% tariffs for generic pharmaceuticals","https://www.supplychaindive.com/news/trump-maps-out-200-tariffs-for-generic-pharmaceuticals/825882/",{"id":89,"title":90,"source":91,"logo":5,"time":71},1288577,"US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028","https://www.pharmaceutical-technology.com/news/donald-trump-us-generic-drug-tariffs/",{"id":93,"title":94,"source":95,"logo":13,"time":96},1288539,"A New Round in US Pharma Tariffs: What’s at Play?","https://www.dcatvci.org/features/a-new-round-in-us-pharma-tariffs-whats-at-play/","4D AGO",{"id":98,"title":99,"source":100,"logo":15,"time":71},1282813,"How Trump’s Drug Tariffs Could Hit Millions of Americans’ Medicine Bills","https://www.newsweek.com/how-trumps-drug-tariffs-could-hit-millions-of-americans-medicine-bills-12226842",{"id":102,"title":103,"source":104,"logo":35,"time":71},1280998,"Shares in Generic-Drug Makers Fall After Trump’s Tariff Plan","https://www.wsj.com/health/pharma/shares-in-generic-drug-makers-fall-after-trumps-tariff-plan-ed8b281c",{"id":106,"title":107,"source":108,"logo":36,"time":71},1280997,"Generic drug tariffs could send prices soaring for millions of Americans","https://www.latimes.com/business/story/2026-07-22/generic-drug-tariffs-could-send-prices-soaring-for-millions-of-americans",{"id":110,"title":111,"source":112,"logo":30,"time":71},1281008,"Roundup: Generic drug tariffs / AI eyewear / Nike’s new China play","https://www.businessreport.com/article/roundup-generic-drug-tariffs-ai-eyewear-nikes-new-china-play",{"id":114,"title":115,"source":116,"logo":28,"time":71},1282805,"Trump's 200% tariff plan may be a bitter pill for US consumers; Dr Reddy's warns of costlier medicines","https://timesofindia.indiatimes.com/business/india-business/trumps-200-tariff-plan-may-be-a-bitter-pill-for-us-consumers-dr-reddys-warns-of-costlier-medicines/articleshow/132562742.cms",{"id":118,"title":119,"source":120,"logo":20,"time":71},1280993,"Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply","https://www.cnbc.com/2026/07/22/trump-generic-drug-tariffs-prices-explained.html",{"id":122,"title":123,"source":124,"logo":37,"time":71},1281003,"What would 200% US tariffs on generic drugs mean for China’s pharmaceutical industry?","https://www.scmp.com/economy/china-economy/article/3361468/what-would-200-us-tariffs-generic-drugs-mean-chinas-pharmaceutical-industry",{"id":126,"title":127,"source":128,"logo":32,"time":71},1288550,"Generic drug sector seeks policy fixes after Trump tariff threat","https://www.reuters.com/legal/litigation/generic-drug-sector-seeks-policy-fixes-after-trump-tariff-threat-2026-07-22/",{"id":130,"title":131,"source":132,"logo":34,"time":71},1279825,"Trump’s 100% Generic Drug Duty Threatens US Low-Cost Supply","https://www.bloomberg.com/news/articles/2026-07-21/trump-plans-100-tariff-on-generic-drugs-from-august-2028",{"id":134,"title":135,"source":136,"logo":5,"time":96},1288571,"Opinion | The problem with RFK Jr.’s crusade against antidepressants","https://www.washingtonpost.com/opinions/2026/07/23/rfk-jrs-crusade-against-ssri-antidepressants-needs-more-research/",{"id":138,"title":139,"source":140,"logo":18,"time":96},1288570,"Trump Plans to Impose 100% Tariffs on Generic Drugs Starting in 2028. What Would That Do to Prices?","https://time.com/article/2026/07/23/trump-generic-drug-tariff-prices-availability-impact/",{"id":142,"title":143,"source":144,"logo":14,"time":96},1288543,"EU Says Generic Medicines Should Be Exempt From U.S. Tariffs","https://www.navlindaily.com/article/31346/eu-says-generic-medicines-should-be-exempt-from-u-s-tariffs",{"id":146,"title":147,"source":148,"logo":24,"time":96},1288542,"Tariff India, and half of America’s medicine cabinet could disappear","https://www.washingtonexaminer.com/op-eds/4658390/tariffs-india-american-medicine/",{"id":150,"title":151,"source":152,"logo":19,"time":71},1288564,"EU says Trump’s new generic drug tariffs won’t hit its exports","https://www.politico.eu/article/eu-donald-trump-new-generic-drug-tariff-export/",{"id":154,"title":155,"source":156,"logo":5,"time":96},1288541,"Generic drug tariffs set to skyrocket in 2028. Consumers could feel impact","https://www.usatoday.com/story/money/2026/07/22/generic-drug-tariffs-trump-consumer-impact/91007261007/",{"id":158,"title":159,"source":160,"logo":26,"time":71},1288563,"Generic drugmaker Sandoz to engage with US after Trump tariff threat","https://www.reuters.com/legal/litigation/generic-drugmaker-sandoz-engage-with-us-after-trump-tariff-threat-2026-07-22/",{"id":162,"title":163,"source":164,"logo":12,"time":96},1288540,"3 U.S. Pharma Stocks Worth Watching After New Import Tariffs","https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/3-us-pharma-stocks-worth-watching-after-new-import-tariffs",{"id":166,"title":167,"source":168,"logo":22,"time":71},1288562,"Trump threatens 100 percent generic drug tariffs beginning in 2028","https://thehill.com/policy/healthcare/5983150-trump-tariffs-generic-drugs/",{"id":170,"title":171,"source":172,"logo":10,"time":96},1288547,"Trump’s 100% Tariffs on Generic Meds Threaten Headaches at Drugstore Checkouts","https://www.thedailyupside.com/industries/healthcare/trumps-threatened-200-tariffs-on-generic-drugs-could-spell-headaches-aat-home-and-abroad/",{"id":174,"title":175,"source":176,"logo":16,"time":177},1288569,"U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns","https://www.cnbc.com/2026/07/24/us-to-see-higher-generic-drug-prices-on-tariffs-indian-pharma-ceo.html","3D AGO",{"id":179,"title":180,"source":181,"logo":5,"time":96},1288546,"Opinion | Trump’s generic drug tariffs will drive up pharmaceutical prices","https://www.washingtonpost.com/opinions/2026/07/22/trumps-generic-drug-tariffs-will-drive-up-pharmaceutical-prices/",{"id":183,"title":184,"source":185,"logo":33,"time":71},1288568,"The Hollowing Out of America’s Medicine Cabinet","https://prosperousamerica.org/the-hollowing-out-of-americas-medicine-cabinet/",{"id":187,"title":188,"source":189,"logo":38,"time":96},1288545,"Trump turns tariff fire on generics with 2028 countdown","https://www.thepharmaletter.com/generics-news/trump-turns-tariff-fire-on-generic-drugmakers-with-2028-countdown",{"id":191,"title":192,"source":193,"logo":27,"time":96},1288544,"Belgium Urges United Europe Response to Trump’s Generic Drug Tariffs","https://ednews.net/en/belgium-urges-united-europe-response-to-trumps-generic-drug-tariffs/",{"id":195,"title":196,"source":197,"logo":39,"time":71},1288548,"Trump plans 100% tariffs on imported generic drugs. Here's what experts say.","https://www.cbsnews.com/news/trump-generic-drug-tariffs-manufacturing/",{"id":199,"title":200,"source":201,"logo":29,"time":71},1282821,"Trump Announces Plan That Could Triple Prescription Drug Prices After Midterms","https://www.yahoo.com/news/politics/articles/trump-announces-plan-could-triple-151502774.html",{"id":203,"title":204,"source":205,"logo":11,"time":71},1281019,"India Gets Another Dose of Trump’s Trade Medicine","https://www.bloomberg.com/news/newsletters/2026-07-22/indian-drugmakers-hit-with-renewed-tariff-threat-from-trump",{"id":207,"title":208,"source":209,"logo":23,"time":71},1281013,"President Trump Announces Phased Generic Drug Tariff Plan: Report","https://www.pharmexec.com/view/president-trump-phased-drug-tariff","#9d4006ff","#9d40064d",1785213076839]